Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program (PHARMAID)

Civil Hospices of Lyon

Status: Unknown

Conditions: Alzheimer Disease

Treatments: Behavioral: Psychosocial intervention; Other: Pharmaceutical care and psychosocial support

Study type: Interventional

Funder types: Other

Identifiers

NCT02802371

69HCL14_0450

Details and patient eligibility

About

Caring for patients with Alzheimer Disease or Related Disorders (ADRD) is accompanied with a caregiver burden that increases with the progression of the disease. This burden can have physical, psychological, emotional, social and financial issue on the informal caregivers who are often represented as hidden secondary patients. They frequently have a higher risk of developing mood disorders as depression, anxiety, stress, sleep disorders and a lower quality of life associated with a greater use of psychotropic drugs. They also incur higher risk of heart disease and mortality. The embrittlement of the caregiver is a major factor of early institutionalization of patient. In the PIXEL study, the mean age of the men caregivers was 73.9 years and 64.8 for the women caregivers. Elderly themselves, especially spouses, the informal caregivers are also exposed to common chronic diseases and associated polypharmacy with a higher risk of developing drug-related problems due to aging and negligence of their own health care. These risks are increased mainly in the elderly because of changes in pharmacokinetic and pharmacodynamic parameters related to aging, acute or chronic diseases and the potentially inappropriate prescription (PIP). Previous studies have shown the effectiveness and positive impact of optimization of the therapeutics by a clinical pharmacist on the reduction of drug-related problems, length of hospital stay, readmission rates, quality of life and mortality. The patient's medication management is usually delegated to the informal caregiver, who must also manage his own treatment. The caregiver may face difficulties with therapeutics (e.g., inappropriate dosage form, adverse effects and patient refusal) that could impact on its compliance with treatment or that of his relative. No previous study has evaluated the impact of pharmaceutical collaborative care including personalized interview with a clinical pharmacist and optimization of drug prescribing among patients with ADRD and their caregivers.

However, many studies have assessed the effectiveness of non-pharmacological interventions on caregiver burden, mood disorders and the patient institutionalization. Meta-analysis showed a moderate improvement of the caregiver burden.

The main objective of the PHARMAID study is to measure the impact of personalized pharmaceutical collaborative care integrated to a multidisciplinary psychosocial program on the burden of ADRD caregivers and assessed at 18-month follow-up.

Enrollment: 240 estimated patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

for the patients:

• Patients aged 65 and over;
• Patients with ADRD;
• Patients suffering from mild to moderate stages of the disease, defined by the Mini-Mental Score Examination (MMSE), with scores of 25 to 16/30;
• Patients living at home;
• Patients received in a geriatric or memory consultation of a study recruiting centers;
• Patients with the ability to express themselves orally or in writing in French sufficiently to carry out clinical assessments;
• Patients who are not opposed to the research;

for the caregivers:

• Caregivers aged 55 and over;
• Nonprofessional caregivers living with the patient or providing support to him/her at least 10 hours a week for the activities of daily living;
• Caregivers with the ability to follow the program at the discretion of the investigator;
• Caregivers with the ability to express themselves orally or in writing in French sufficiently to carry out clinical assessments;
• Caregivers who are not opposed to the research.

Exclusion criteria

for the patients:

• Institutionalized patients.

for the caregivers:

• Caregivers involved in another support program for the caregivers;
• Caregivers whose the level of acceptance of the disease does not allow the participation in the study.

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

240 participants in 3 patient groups

control group

No Intervention group

Description:

Patients and caregivers randomized in the control group will receive the current management in geriatric or memory consultation without multidisciplinary psychosocial intervention and pharmaceutical collaborative care.There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, but the recommendations will not be transmitted to the referring physicians of patients and caregivers.

Psychosocial intervention

Active Comparator group

Description:

Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.

Treatment:

Behavioral: Psychosocial intervention

Pharmaceutical care and psychosocial support

Experimental group

Description:

Pharmaceutical collaborative care integrated in a psychosocial program. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of caregivers; 2) collective session on medication management; and 3) optimization of drug prescribing. These collective and individual sessions of pharmaceutical care will allow an extended 18 month follow-up. Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.

Treatment:

Other: Pharmaceutical care and psychosocial support